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compared to AT- and CB-MSC. We have analyzed the molecular
proﬁle of BM-MSC, AT-MSC and CB-MSC. Gene expressions in
BM-MSC preparations correlated with their potential for driving
HPC into self-renewal. Following genes were up-regulated: cad-
herin11, N-cadherin, ITGA1, ITGA5 and ITGB1, VCAM1, pro-
tocadherin18, SDF-1. Western blot analysis also conﬁrmed higher
protein expression of ITGB1, FN1, cadherin11 and N-cadherin in
BM-MSC compared to AT-MSC and CB-MSC.
BM-MSC therefore represent a surrogate model for the human
hematopoietic niche. Primitive subsets of HPC demonstrated a
high afﬁnity to BM-MSC compared to more differentiated frac-
tions. This correlated with the expression of cadherin 11, N-
cadherin and 	1 integrins.
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PREVENTIVE HEALTH BEHAVIORS OF LONG-TERM HEMATOPOIETIC
CELL TRANSPLANT SURVIVORS
Bishop, M.M.1, Beaumont, J.L.2, Lee, S.J.3, Andrykowski, M.A.4,
Rizzo, J.D.5, Wingard, J.R.1 1University of Florida, Gainesville, FL;
2Evanston Northwestern Healthcare, Evanston, IL; 3Fred Hutchinson
Cancer Research Center, Seattle, WA; 4University of Kentucky, Lexing-
ton, KY; 5Medical College of Wisconsin, Milwaukee, WI.
Hematopoietic cell transplantation (HCT) is a life-saving ther-
apy for many patients with leukemia, lymphoma, and breast cancer.
However, it is not known how many, and to what extent, survivors
participate in healthy behaviors and recommended preventive ser-
vices to avoid future health problems after transplant. We collected
self-reported information on health-preserving behaviors as part of
a large, cross-sectional study of long-term HCT survivors, spouses,
and acquaintances. Information on both health provider indepen-
dent (behaviors that do not require medical contact, i.e., tobacco
and alcohol avoidance, exercise) and health provider dependent
(e.g., cholesterol test, blood pressure check, sigmoidoscopy, skin
exam, breast exam, mammogram, immunizations) practices was
obtained through telephone interviews. Participants included 662
HCT survivors (41% allogeneic and 59% autologous) recruited
from 40 North American transplant centers, 177 spouses, 158
controls matched to survivors on sex, age, martial status, and
education level. 238 (36%) of HCT survivors had had acute leu-
kemia, 128 (20%) CML, 131 (20%) lymphoma, and 154 (23%)
breast cancer. Survivors were predominately Caucasian (92%),
married (73%), female (62%), and well-educated (71% had post
high school education). Mean age was 49 yrs (SD10; range 21-77
yrs) and mean time since HCT was 7 yrs (SD 3; range 2-23 yrs).
84% of survivors reported that they never smoke, 59% never drink
alcohol, and 35% often/always exercise at least 20 minutes/day 3
times/week. Despite 94% of survivors reporting they had a physi-
cian and 92% having health insurance coverage, only 56% of
survivors reported having received a ﬂu shot in the last year.
Although allogeneic survivors were more likely than autologous
survivors to report having had a skin exam in the past year (54% vs.
43%, p.002), those rates were low given their vulnerability to
skin cancer. Additional comparisons between type of transplant, as
well as time since transplant and cohort group (survivors, spouses,
matched controls) are underway. Overall self-reported compliance
with recommended health behaviors in HCT survivors was rea-
sonably good compared to the general population, but there re-
mains considerable room for improvement. Survivors’ frequent
contact with the medical system and past experience with illness
provide opportunities to improve prevention screening and to
promote healthy behaviors in HCT survivors and their families.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (SCT) IN FANCONI
ANEMIA (FA) PATIENTS: HOW LONG IS LONG TERM FOLLOW-UP?
Bonﬁm, C.1, Bitencourt, M.1, deMedeiros, C.1, Setubal, D.1, Ruiz, J.1,
Quiroga, M.1, Beltrame, M.1, Funke, V.1, Zanis-Neto, J.1,
Pasquini, R.1 1Stem Cell Transplantation Center - Federal University of
Parana, Curitiba, PR, Brazil.
FA is an autosomal recessive disorder characterized by progres-
sive bone marrow failure, congenital abnormalities and a predis-
position to malignancies. SCT is the only treatment that can
restore normal hematopoiesis but long term follow up(LTFU) is
essential especially because of the high incidence of cancer in
these pts. From 1983 to 2006, 168pts were transplanted in our
BMT Unit. In this study we evaluated the outcome of 43 pts
transplanted between 1983-1996 from related bone marrow
compatible donors. Aplastic phase:40pts, MDS/Leukemia:3pts.
No radiotherapy was given in the preparatory regimen. 36/43pts
survived 28d and were evaluable for engraftment. 34 had a
sustained hematological engraftment and 2pts had a partial
engraftment. One pt with previous MDS relapsed and died after
a 2nd BMT. No other pt rejected their graft. 19pts died between
1-3101d after SCT(M:48d) due to infections or
hemorrhage(13pts), tongue carcinoma(2pts) and extensive C-
GVHD/ infections (5pts). Twenty-four pts are alive between
10-18,3years after BMT(M:12,4years). Median age was 8y(3-32)
at SCT and 20,5y(13-47) at most recent evaluation.Gender:9F/
15M. Aplastic phase: all pts. Preparatory regimen: CY200: 3pts;
CY140ATG:8pts; CY120:4pts; Cy100:9pts. GVHD prophy-
laxis: cyclosporine (Csa)MTX: 20pts; Csa  steroids:4pts.
Mucositis grade II-IV occurred in 19pts and severe hemorrhage
in 5pts. A-GVHD grade II-III: 2pts. Extensive C-GVHD:
2pts.Chimerism was evaluated by VNTR analysis in 21 pts and
by cytogenetics or blood type in 3 pts. All pts have normal blood
counts and only 3 pts had a mixed chimerism (80-90% of
donor’s cells). One pt developed esophagus stenosis after SCT
due to severe mucositis. 18pts were transplanted before the age
of 12y and only 2pts(female/male) needed hormonal replace-
ment to enter puberty. Reproductive function: Only 2pts be-
came pregnant 6y and 11 y after SCT. One of them delivered a
healthy child and the other had a spontaneous abortion. Hypo-
thyreoidism was detected in 2pts. Malignancies developed in
2/24pts (basal cell carcinoma and tongue carcinoma). Alto-
gether, 3/43pts developed tongue carcinoma. All of them had
grade IV mucositis and only one had severe acute and chronic
GVHD. Conclusion: FA pts treated with SCT should be care-
fully monitored for life time in order to detect cancer and other
complications.
127
GENE EXPRESSION SIGNATURES THAT PREDICT HUMAN RADIATION
EXPOSURE
Meadows, S.1, Dressman, H.1, Muramoto, G.1, Chao, N.J.1,
Ginsburg, G.1, Nevins, J.P.1, Chute, J.P.1 1Duke University Medical
Center, Durham, NC.
The capacity to assess environmental inputs to biological
phenotypes is limited by methods that can accurately and quan-
titatively measure these contributions. One such example can be
seen in the context of exposure to ionizing radiation. The
purposeful detonation of radiological or nuclear materials by
terrorists has been recognized as a major threat to U.S. national
security. Unfortunately, no rapid or practical assays are available
to measure internal biodosimetry in a large population of af-
fected individuals. To address this problem, we have made use
of gene expression analysis of peripheral blood mononuclear
cells (PB MNCs) to develop expression proﬁles that accurately
reﬂect prior radiation exposure. Importantly, we demonstrate
that expression proﬁles can be developed that not only predict
radiation exposure in mice but also distinguish the level of
radiation exposure, ranging from 50 cGy to 1000 cGy. Likewise,
a molecular signature of radiation response developed solely
from analysis of peripheral blood samples from irradiated stem
cell transplant patients can predict and distinguish irradiated
human PB samples from non-irradiated samples with an accu-
racy of 90%, sensitivity of 85% and speciﬁcity of 94%. We
further demonstrate that a radiation proﬁle developed in the
mouse can correctly distinguish PB samples from irradiated and
non-irradiated human patients with an accuracy of 77%, sensi-
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tivity of 82% and speciﬁcity of 75%. Taken together, these data
demonstrate that molecular proﬁles can be generated which are
highly predictive of different levels of radiation exposure in
mice and humans. We suggest that this approach, with addi-
tional reﬁnement, could provide a method to assess the effects of
various environmental inputs into biological phenotypes as well
as providing a more practical application of a rapid molecular
screening test for the diagnosis of radiation exposure.
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HIGH PREVALENCE OF BONE LOSS IN LONG TERM SURVIVORS FOL-
LOWING ALLOGENEIC BONE MARROW AND PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION
Donohue, T.B.1, Savani, B.N.1, Shenoy, A.1, Kozanas, E.1,
Singh, A.K.2, Childs, R.W.1, Barrett, A.J.1 1Stem Cell Transplant
Secotion, Hematology Branch; NHLBI, National Institutes of Health,
Bethesda, MD; 2Radiation Biology Section; NCI, National Institutes of
Health, Bethesda, MD.
Bone loss (osteopenia/osteoporosis) is a complication following
allogeneic stem cell transplantation (SCT). After written consent
patients surviving more than three years post-transplant were en-
rolled in a long-term follow-up study (started in April 2005) which
included an annual DEXA scan. Sixty-three patients (median age
35 years) received a fractionated total body irradiation (TBI) (12-
13.6 Gy) based myeloablative SCT (MST) and 9 patients (median
age 37 years) received a non-TBI non-myeloablative SCT (NST).
Age of patients at transplantation ranged from 6 to 66 (median 35
years). The indication for SCT was CML (43), MDS (11), AML
(11), ALL (3), CLL (2), SAA (1), and mastocytosis (1). Seventy-two
(41M,31F) patients underwent DEXA scanning. Seventy (97%)
patients are alive at a median follow-up of 73 months (range
32-155); Acute graft versus host disease (GVHD) occurred in 41
(57%) patients and chronic GVHD in 61 (85%). Twelve (17%)
patients at a median follow up 37 (range 32-106 months) were
receiving immunosuppressive therapy (IST) for chronic GVHD at
the time of analysis. All patients were advised to take vitamin D and
calcium supplements after transplantation and all but one female
were taking hormone replacement therapy at the time of DEXA
scanning. Fifty-three (74%) of patients had bone loss in at least one
site measured - 30 (42%) with osteopenia and 23 (32%) with
osteoporosis. There was a preponderance of osteopenia and osteo-
porosis in typical sites such as AP spine (22% and 18%); femoral
neck (46% and 6%); and femur (Ward’s area) (38% and 8%); total
hip (36% and 1%); but also in the forearm (24% and 13%) likely
related to steriod therapy. Mean T score of adult patients was
-1.8  0.16 (male -1.9  0.2; female -1.6  0.3); while mean Z
score of 5 children (age 18) was -1.6  0.45. Factors associated
with signiﬁcant increase risk of bone loss were: age more than
median (p0.03) and prolonged IST (12/12 vs. 41/60; p0.017 for
bone loss and 8/12 vs.15/60; p0.008 for osteoporosis). When
patient age was analyzed by quartiles, the oldest quartile (range
44-66) was profoundly impacted for osteoporosis (mean T score
-2.3 0.25; p0.016). There was no signiﬁcant difference in bone
loss with regard to sex, stem cell source, disease, TBI dose, acute
GVHD, or chronic GVHD. In summary, we found a very high
prevalence of bone loss in long term survivors of SCT. Bone loss
is associated with older age at transplant and continuing treatment
of chronic GVHD.
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15 YEARS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BETA
THALASSEMIA MAJOR IN TEHRAN
Gavamzadeh, A.1, Ali Mogaddam, K.1, Nedaeifard, L.1, Jahani, M.1,
Mousavi, A.1, Iravani, M.1, Bahar, B.1, Khodabandelu 1 Hematology-
Oncology and BMT Research Center, Tehran University of Medical
Sciences, Tehran, Islamic Republic of Iran.
Objective: Beta Thalassemia Major is the most common type of
haemoglobinopathies in Iranian patients. We reported results of 15
years HSCT in our centre.
Method: 277 Beta Thalassemia Major Patients, 158 male and
119 female with median age of 6 years old (range 2.5-26 y), have
been transplanted from 1991 till march 2006 in our centre.
92 patients were class one, 103 class two and 74 class three
according to Dr.Lucarelli classiﬁcation. They have received
allogeneic transplantation from 266 HLA full matched siblings
and 11 other relatives. Source of hematopoietic cells were 136
bone marrow, 133 peripheral blood and 8 cord blood. The most
common conditioning regimen was Bu/Cy without TBI and
their GVHD prophylaxis regimen was Cyclosporine  Metho-
traxate.
Results: 229 (82.7%) patients are alive and 48 (17.3) dead.
Acute GVHD occurred in 61.3% patients and chronic GVHD
in 4.7% patients and both type in 34% patients. Graft rejection
occurred in 60 (21.7%) patients. The most common cause of
death was acute and chronic GVHD. Venooclussive disease
occurred in 17 patients. Five years overall (OS) and thalassemia
free survival (DFS) were 79% and 65% respectively. OS and
DFS of transplanted patients from HLA- identical siblings were
better than transplanted patients from other relatives’ donors.
There were not any signiﬁcant differences in OS of patients in
different classes of disease or sources of HCT. But DFS of class
one was better than three. OS and DFS were better in patients
with acute GVHD and older donors.
Conclusion: HCT based on our experience and other docu-
mented studies is acceptable treatment for Beta Thalassemia
Major with better result in younger patients.
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THE INCIDENCE OF SECONDARY MALIGNANCY AFTER STEM CELL
TRANSPLANTATION, THE IMPORTANCE OF TOTAL BODY IRRADIATION
Ghavamzadeh, A.1, Samiee, S.1, Mahdavi, N.1, Bakhti, O.1,
Jahani, M.1, Alimoghaddam, K.1, Iravani, M.1, Bahar, B.1,
Khodabandeh, A.1, Mousavi, A.1 1Hematology-Oncology and BMT Re-
search Center, Tehran University of Medical Sciences, Tehran, Islamic
Republic of Iran.
Purpose: In this study we studied the records of 1586 recipi-
ents of autologous or allogeneic-related and -unrelated and
syngeneic bone marrow transplants (BMTs) between 1991 till
2006 to determine the incidence of secondary malignancies and
importance of Total Body Irradiation as a risk factor.
PATIENTS AND METHODS : 829 patients were under-
gone transplantation for acute lymphocytic leukemia (ALL; n 
212), acute myelogenous leukemia (AML; n  429), and chronic
myelogenous leukemia (CML; n  188) while 162 patients for
Lymphoma, 98 for aplastic anemia (AA), 284 for Thalassemia
and 213 patients for a variety of other hematologic and nonhe-
matologic disorders, malignant and nonmalignant. Condition-
ing regimens included high-dose chemotherapy without total-
body irradiation (TBI). Patients who were missed to follow-up
were excluded from the study on the time of missed to follow up.
RESULTS: 9 patients developed 9 secondary cancers for a one
year risk of 1.2%, ﬁve year risk of 2.4% and ten year risk of
2.9%. Of all the 9 patients 5 (55.5) were male, and 4(44.4%)
were female. The median age was 21 years old; with minimum
and maximum of 13 and 28 y/o respectively. 6(66.6%) patients
received allogeneic stem cell transplantation and 3(33.3%) re-
ceived autologous transplantation. 5 patients (55.5%) had pe-
ripheral blood as graft type. The conditioning regimen for
4(44.4%) of patients was Busulphan and Cyclophosphamide, 1
patient had Busulphane, Cyclophosphamide and Etoposide, 3 of
them had Cyclophosphamide, Etoposide and Ara-C. The other
1 patient had ATG, Cyclophosphamaide and Fludarabine as
conditioning regimen. The median follow-up duration for all
our patients was 376 days, (1-4749) which was 300 days for these
9 patients who developed new malignancy. (45-1125) .Overall
Mortality Rate is 66.6% and the cause of death in 33.3% of
patients is new malignancy.
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